Company Overview - VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need [3]. Conference Participation - VYNE's management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 [1]. - The fireside chat is scheduled for 11:00 am ET on the same day [2]. - A webcast replay will be available on VYNE's website for 90 days following the event [2]. Product Development - VYNE's proprietary BET inhibitors, part of its InhiBET™ platform, aim to address limitations of earlier generation BET inhibitors by utilizing alternative administration routes and enhanced selectivity [3].

Company Overview - VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions with high unmet need [3]. Conference Participation - VYNE's management will participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 [1]. - A fireside chat is scheduled for March 27, 2025, at 11:00 am ET, with a webcast replay available on the VYNE website for 90 days following the event [2]. Product Development - VYNE's proprietary BET inhibitors, part of its InhiBET™ platform, aim to overcome limitations of early generation BET inhibitors by utilizing alternative routes of administration and enhanced selectivity [3].